Drug Profile
Research programme: targeted anticancer therapies - TMC/Elan
Alternative Names: Targeted anticancer therapies research programme - TMC/ElanLatest Information Update: 03 Apr 2003
Price :
$50
*
At a glance
- Originator Elan Corporation; Targeted Molecules Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Apr 2003 Discontinued - Preclinical for Cancer in Ireland (unspecified route)
- 03 Apr 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 25 Mar 2003 No development reported - Preclinical for Cancer in Ireland (unspecified route)